SoftBank Vision Fund 2 led a $165m funding round for Karius, a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test, with additional participation from General Catalyst, HBM Healthcare Investments, and existing investors Khosla Ventures and LightSpeed Venture Partners. "This transformative round will allow Karius to help more patients faster, fuel the next wave of clinical studies, and accelerate technology innovation. We are humbled to be part of the team that delivered the first clinical applications of microbial cell-free DNA and are excited about what's ahead for Karius," Mickey Kertesz, Karius CEO.